CRYOPORT, INC. Cost, Direct Labor
CRYOPORT, INC. (CYRX) reported Cost, Direct Labor of $8.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostDirectLabor · last filed 2026-08-06
- CRYOPORT, INC. cost, direct labor for the quarter ending 2026-06-30 was $8.00M, a 15.94% increase year-over-year.
- CRYOPORT, INC. cost, direct labor for the quarter ending 2026-03-31 was $7.50M, a 8.70% increase year-over-year.
- CRYOPORT, INC. cost, direct labor for the quarter ending 2025-12-31 was $6.50M, a 25.00% increase year-over-year.
- CRYOPORT, INC. cost, direct labor for the quarter ending 2025-09-30 was $5.90M, a 11.32% increase year-over-year.
- CRYOPORT, INC. cost, direct labor for fiscal 2025 was $26.20M, a 11.49% increase from fiscal 2024.
- CRYOPORT, INC. cost, direct labor for fiscal 2024 was $23.50M, a 5.24% decline from fiscal 2023.
- CRYOPORT, INC. cost, direct labor for fiscal 2023 was $24.80M.
| Period end | Cost, Direct Labor 3 month | Cost, Direct Labor 6 month | Cost, Direct Labor 9 month | Cost, Direct Labor 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.00M 10-Q · filed 2026-08-06 | $15.50M 10-Q · filed 2026-08-06 | $22.00M derived: sum of 3 quarters · filed 2026-08-06 | $27.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $7.50M 10-Q · filed 2026-05-05 | $14.00M derived: sum of 2 quarters · filed 2026-05-05 | $19.90M derived: sum of 3 quarters · filed 2026-05-05 | $26.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $6.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $12.40M derived: sum of 2 quarters · filed 2026-03-05 | $19.30M derived: sum of 3 quarters · filed 2026-08-06 | $26.20M 10-K · filed 2026-03-05 |
| 2025-09-30 | $5.90M 10-Q · filed 2025-11-06 | $12.80M derived: sum of 2 quarters · filed 2026-08-06 | $19.70M 10-Q · filed 2025-11-06 | $24.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.90M 10-Q · filed 2026-08-06 | $13.80M 10-Q · filed 2026-08-06 | $19.00M derived: sum of 3 quarters · filed 2026-08-06 | $24.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.90M 10-Q · filed 2026-05-05 | $12.10M derived: sum of 2 quarters · filed 2026-05-05 | $17.40M derived: sum of 3 quarters · filed 2026-05-05 | |
| 2024-12-31 | $5.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $10.50M derived: sum of 2 quarters · filed 2026-03-05 | $23.50M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $5.30M 10-Q · filed 2025-11-06 | $18.30M 10-Q · filed 2025-11-06 | ||
| 2023-12-31 | $24.80M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |